Colorectal Cancer and Wnt Signalling
Group Leader:
Prof Owen Sansom
We are interrogating the molecular underpinnings of epithelial cancers to identify early disease diagnostic biomarkers and develop stage- and subtype-specific targeted therapies. We utilise omics and spatial biology technologies in state-of-the-art preclinical models harbouring key driver mutations and compare these to human disease. These disease-positioned mouse and organoid models are providing a tractable means to observe epithelial-cell plasticity and adaptive therapeutic responses in real-time in and ex vivo, with the overarching goal of translating promising preclinical findings into a tangible clinical benefit.
Lab Reports
click here to read
Recent Publications
click here to read
Lab Members
click here to read
Recent Publications
2026
Centeno PP, Chester C, Kanellos G, Ford CA, Cammareri P, Inman GJ, Jamieson T, Ridgway RA, Marais R, Campbell AD, Sansom OJ. SOX2 confers tumour permissiveness in a specific skin progenitor population. Nat Commun. 2026;17(1):304.
Corry SM, Sakhnevych S, Mohamed NE, Malla SB, Byrne R, Young A, Amirkhah R, Bull C, Lees A, Redmond K, Lannagan TRM, Ridgway RA, Taggart FR, Fisher NC, Maughan T, Lawler M, Campbell AD, Leedham SJ, Ryan AE, Longley DB, Small DM, Sansom OJ, Dunne PD. Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state. Commun Biol. 2026.
Mulholland-Illingworth EJ, Moore JW, Lin M, Amirkhah R, Grzesiak L, Ligeza A, Bull JA, Boen J, Valbuena GN, Gillespie MA, Lannagan TRM, Gilroy K, Mills ML, Corry SM, Ridgway RA, Belnoue-Davis HL, Dunne PD, Sansom OJ, Byrne HM, Leedham SJ. Therapeutic manipulation and spatial quantification of the tumor microenvironment in colorectal cancer. iScience. 2026;29(4):115193.
White M, Campbell AD, Sansom OJ. The cartography of KRAS inhibitor resistance in colorectal cancer. Cancer Cell. 2026.
2025
Cammareri P, Raponi M, Hong Y, Billard CV, Peckett N, Zhu Y, Velez-Bravo FD, Younger NT, Dunican DS, Pohl S, Bastem Akan A, Doleschall NJ, Falconer J, White M, Quinn J, Pennel K, Garau R, Malla SB, Dunne PD, Meehan RR, Sansom OJ, Edwards J, Dunlop MG, Din FVN, Tejpar S, Steele CW, Myant KB. Loss of colonic fidelity enables multilineage plasticity and metastasis. Nature. 2025.
Centeno PP, Chester C, Ford CA, Ridgway RA, Cammareri P, Jamieson T, Marais R, Campbell AD, Sansom OJ. Epidermal tumour-resistant progenitors require SOX2-driven developmental reprogramming to drive tumorigenesis. bioRxiv. 2025:2025.2001.2023.634502.
Cong B, Thakur T, Uribe AH, Stamou E, Gopinath S, Sansom O, Maddocks O, Cagan R. Colon cancer cells evade drug action by enhancing drug metabolism. Oncogene. 2025.
Dexter A, Thomas SA, Steven RT, Robinson KN, Taylor AJ, Elia EA, Nikula C, Campbell AD, Panina Y, Najumudeen AK, Yan B, Grabowski P, Hamm G, Swales J, Tripp A, Poulogiannis G, Yuneva MO, Barry S, Goodwin RJA, Sansom OJ, Takats Z, Bunch J. A New Approach to Large Multiomics Data Integration. Anal Chem. 2025.
Ford CA, Koludrovic D, Centeno PP, Foth M, Tsonou E, Vlahov N, Sphyris N, Gilroy K, Bull C, Nixon C, Serrels B, Munro AF, Dawson JC, Carragher NO, Pavet V, Hornigold DC, Dunne PD, Downward J, Welch HCE, Barry ST, Sansom OJ, Campbell AD. Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma. Cancer Res. 2025;85(4):808-824.
Goodwin RJA, Marshall JF, Poulogiannis G, Yuneva M, Brindle KM, Takáts Z, Sansom OJ, Bunch J, Barry ST. Visualizing Cancer Heterogeneity at the Molecular and Cellular Levels: Lessons from Rosetta. Cancer Discov. 2025(1):34-38.
Jarman EJ, Martinez Lyons A, Yao Y, Rozyczko A, Waddell SH, Gradinaru A, Olaizola P, Davies K, Guest RV, Röessler S, Kendall TJ, Sansom OJ, Khamseh A, Boulter L. Epithelial state-transitions permit inflammation-induced tumorigenesis. bioRxiv. 2025:2025.2006.2022.660911.
Kanellos G, Giacomelli C, Raven A, Vlahov N, Jin H, Herviou P, Malla SB, Nasreddin N, Centeno PP, Alexandrou C, Gilroy K, Baird RL, Pennel K, Munro J, Waldron JA, Hall H, Officer-Jones L, Bryson S, Strathdee D, Lilla S, Zanivan S, Morrison V, Nixon C, Ridgway RA, Miller C, Knight JRP, Campbell AD, Dunne PD, Le Quesne J, Edwards J, Park PJ, Bushell M, Sansom OJ. Nucleophosmin supports WNT-driven hyperproliferation and tumor initiation. Nat Genet. 2025;58:100-115.
Lee CY, Dean I, Richoz N, Li Z, Kennedy BC, Vettore LA, Samarakoon Y, Gilroy KL, Hasegawa T, Carlesso G, Hammond SA, Dovedi SJ, Sansom OJ, Tuong ZK, Halim TY, Withers DR, Clatworthy MR. In vivo labelling resolves distinct temporal, spatial, and functional properties of tumour macrophages, and identifies subset-specific effects of PD-L1 blockade. Cancer Immunol Res. 2025.
Ling S, Dexter A, Race AM, Sharma S, Hamm G, Polanska UM, Marshall JF, Takats Z, Brindle K, Yuneva MO, Poulogiannis G, Campbell AD, Sansom OJ, Goodwin RJA, Bunch J, Barry ST. Use of metabolic imaging to monitor heterogeneity of tumour response following therapeutic mTORC1/2 pathway inhibition. Dis Model Mech. 2025;18(2).
Mulholland EJ, Belnoue-Davis HL, Valbuena GN, Gunduz N, Ligeza A, Lin M, Biswas S, Gil Vasquez E, Omwenga S, Nasreddin N, Hodder MC, Wang LM, Ng AS, Jennings E, Midwood KS, Dedi N, Irshad S, Ridgway RA, Phesse TJ, East J, Tomlinson IP, Davies GC, Sansom OJ, Leedham SJ. Epithelial GREMLIN1 disrupts intestinal epithelial-mesenchymal crosstalk to induce a wnt-dependent ectopic stem cell niche through stromal remodelling. Nat Commun. 2025;16(1):5167.
Müller M, May S, Hall H, Kendall TJ, McGarry L, Blukacz L, Nuciforo S, Georgakopoulou A, Jamieson T, Phinichkusolchit N, Dhayade S, Suzuki T, Huguet-Pradell J, Powley IR, Officer-Jones L, Pennie RL, Esteban-Fabró R, Gris-Oliver A, Pinyol R, Skalka GL, Leslie J, Hoare M, Sprangers J, Malviya G, Mackintosh A, Johnson E, McCain M, Halpin J, Kiourtis C, Nixon C, Clark G, Clark W, Shaw R, Hedley A, Drake TM, Tan EH, Neilson M, Murphy DJ, Lewis DY, Reeves HL, Le Quesne J, Mann DA, Carlin LM, Blyth K, Llovet JM, Heim MH, Sansom OJ, Miller CJ, Bird TG. Human-correlated genetic models identify precision therapy for liver cancer. Nature. 2025.
Mzoughi S, Schwarz M, Wang X, Demircioglu D, Ulukaya G, Mohammed K, Zorgati H, Torre D, Tomalin LE, Di Tullio F, Company C, Dramaretska Y, Leushacke M, Giotti B, Lannagan TR, Lozano-Ojalvo D, Karras P, Vermeulen PB, Hasson D, Sebra R, Tsankov AM, Sansom OJ, Marine JC, Barker N, Gargiulo G, Guccione E. Oncofetal reprogramming drives phenotypic plasticity in WNT-dependent colorectal cancer. Nat Genet. 2025;57(2):402-412.
Raven A, Gilroy K, Jin H, Waldron JA, Leslie H, Munro J, Hall H, Ridgway RA, Ford CA, Gulhan DC, Vlahov N, Mills ML, Hartley A, Anderson E, Bryson S, Sphyris N, Müller M, May S, Cadden B, Nixon C, Waddell SH, Guest R, Boulter L, Barker N, Clevers H, Zhu H, Ivaska J, Strathdee D, Miller CJ, Jamieson NB, Bushell M, Park PJ, Bird TG, Sansom OJ. Hepatic zonation determines tumorigenic potential of mutant β-catenin. Nature. 2025;649:739-748.
Salvador-Barbero B, Alatsatianos M, Morton JP, Sansom OJ, Hogan C. KRASG12D cells override homeostatic cell elimination mechanisms in adult pancreas via Wnt5a and cell dormancy. Gastroenterology. 2025;169(5):983-999.e921.
Torang A, Kirov AB, Lammers V, Cameron K, Wouters VM, Jackstadt RF, Lannagan TRM, de Jong JH, Koster J, Sansom O, Medema JP. Enterocyte-like differentiation defines metabolic gene signatures of CMS3 colorectal cancers and provides therapeutic vulnerability. Nat Commun. 2025;16(1):264.
White M, Mills ML, Millett LM, Gilroy K, Hong Y, Zeiger LB, Simpson RJ, Corry SM, Ligeza A, Lannagan TRM, Susanti S, Ridgway RA, Yazgili AS, Grzesiak L, Amirkhah R, Ford CA, Vlahov N, Tovell H, Officer-Jones L, Ficken C, Pennie R, Najumudeen AK, Raven A, Nasreddin N, Chauhan E, Papanastasiou AS, Nixon C, Morrison V, Jackstadt R, Graham JS, Miller CJ, Ross SJ, Barry ST, Pavet V, Wilson RH, Le Quesne J, Dunne PD, Tejpar S, Leedham S, Campbell AD, Sansom OJ. MAPK-driven epithelial cell plasticity drives colorectal cancer therapeutic resistance. Nature. 2025.
Whyte D, Fisher SL, McKenzie CGJ, Sumpton D, Dhayade S, Dornier E, Moore M, Novo D, Peters J, Wiesheu R, Gounis MD, Watt DM, Mackey JBG, McFarlane AJ, Fercoq F, Dehesa Caballero C, Redmond KL, Mitchell LE, Anderson E, Thomson G, Hedley A, Clark W, Leroi S, Dzierozynski LN, Apiz Saab JJ, Lewis CA, Muir A, Halbrook CJ, Strathdee D, Jackstadt R, Nixon C, Dunne P, Carlin LM, Macpherson IR, Roberts EW, Coffelt SB, Blyth K, Sansom OJ, Norman JC, Vande Voorde J, Clarke CJ. Uridine phosphorylase-1 supports metastasis by altering immune and extracellular matrix landscapes. EMBO Rep. 2025.
Wouters VM, Helderman R, Cameron K, van der Hooff SR, Torang A, van den Bergh S, Jackstadt R, Sansom OJ, van Neerven SM, Medema JP. CDX2 downregulation regulates intrinsic WNT pathway activation, dictating metastasis in APC and CTNNB1 wildtype colorectal cancer. Oncogene. 2025;44:2091-2102.
2024
Corry SM, Sakhnevych S, Mohamed NE, Malla SB, Byrne R, Young A, Amirkhah R, Bull C, Lees A, Redmond K, Lannagan T, Ridgway R, Taggart FR, Fisher NC, Maughan T, Lawler M, Campbell A, Leedham SJ, Ryan AE, Longley DB, Small D, Sansom OJ, Dunne PD. Viral mimicry redirects immunosuppressed colorectal tumour landscapes towards a proinflammatory and CMS1-like regenerative state. bioRxiv. 2024:2024.2011.2028.625928.
Domingo E, Kelly C, Hay J, Sansom O, Maka N, Oien K, Iveson T, Saunders M, Kerr R, Tomlinson I, Edwards J, Harkin A, Nowak M, Koelzer V, Easton A, Boukovinas I, Moustou E, Messaritakis I, Chondrozoumaki M, Karagianni M, Pagès F, Arnoux F, Lautard C, Lovera Y, Boquet I, Catteau A, Galon J, Souglakos I, Church DN. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies. J Clin Oncol. 2024:Jco2301648.
Fetit R, McLaren A, White M, Mills ML, Falconer J, Cortes-Lavaud X, Gilroy K, Lannagan TR, Ridgway RA, Nixon C, Naiker V, Njunge R, Clarke CJ, Whyte D, Kirschner K, Jackstadt R, Norman JC, Carlin LM, Campbell AD, Sansom OJ, Steele CW. Characterising neutrophil subtypes in cancer using scRNA sequencing demonstrates the importance of IL-1β/CXCR2 axis in generation of metastasis specific neutrophils. Cancer Res Commun. 2024.
Fey SK, Najumudeen AK, Watt DM, Millett LM, Ford CA, Gilroy K, Simpson RJ, McLay K, Upstill-Goddard R, Chang D, Clark W, Nixon C, Birch JL, Barry ST, Morton JP, Campbell AD, Sansom OJ. KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition. Cancer Res. 2024.
Ford CA, Koludrovic D, Centeno PP, Foth M, Tsonou E, Vlahov N, Sphyris N, Gilroy K, Bull C, Nixon C, Serrels B, Munro AF, Dawson JC, Carragher NO, Pavet V, Hornigold DC, Dunne PD, Downward J, Welch HC, Barry ST, Sansom OJ, Campbell AD. Targeting the PREX2/RAC1/PI3Kβ Signaling Axis Confers Sensitivity to Clinically Relevant Therapeutic Approaches in Melanoma. Cancer Res. 2024.
Frei AL, McGuigan A, Sinha R, Jabbar F, Gneo L, Tomasevic T, Harkin A, Iveson T, Saunders MP, Oien KA, Maka N, Pezzella F, Campo L, Browne M, Glaire M, Kildal W, Danielsen HE, Hay J, Edwards J, Sansom O, Kelly C, Tomlinson I, Kerr R, Kerr D, Domingo E, Church DN, Koelzer VH. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II-III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis. Lancet Oncol. 2024;25(2):198-211.
Harryvan T, Abudukelimu S, Stouten I, van der Wel E, Janson S, Lenos K, Lannagan T, White M, Sansom O, Verdegaal E, Hawinkels L. TGFβ signaling in cancer-associated fibroblasts drives a hepatic gp130-dependent pro-metastatic inflammatory program in CMS4 colorectal cancer subtype. bioRxiv. 2024:2024.2006.2025.600311.
Kiourtis C, Terradas-Terradas M, Gee LM, May S, Georgakopoulou A, Collins AL, O’Sullivan ED, Baird DP, Hassan M, Shaw R, Tan EH, Müller M, Engelmann C, Andreola F, Hsieh Y-C, Reed LH, Borthwick LA, Nixon C, Clark W, Hanson PS, Sumpton D, Mackay G, Suzuki T, Najumudeen AK, Inman GJ, Campbell A, Barry ST, Quaglia A, Morris CM, LeBeau FEN, Sansom OJ, Kirschner K, Jalan R, Oakley F, Bird TG. Hepatocellular senescence induces multi-organ senescence and dysfunction via TGFβ. Nature Cell Biology. 2024.
Lilja J, Kaivola J, Conway JRW, Vuorio J, Parkkola H, Roivas P, Dibus M, Chastney MR, Varila T, Jacquemet G, Peuhu E, Wang E, Pentikäinen U, Martinez DPI, Hamidi H, Najumudeen AK, Sansom OJ, Barsukov IL, Abankwa D, Vattulainen I, Salmi M, Ivaska J. SHANK3 depletion leads to ERK signalling overdose and cell death in KRAS-mutant cancers. Nat Commun. 2024;15(1):8002.
Loi P, Schade AE, Rodriguez CL, Krishnan A, Perurena N, Nguyen VTM, Xu Y, Watanabe M, Davis RA, Gardner A, Pilla NF, Mattioli K, Popow O, Gunduz N, Lannagan TRM, Fitzgerald S, Sicinska ET, Lin JR, Tan W, Brais LK, Haigis KM, Giannakis M, Ng K, Santagata S, Helin K, Sansom OJ, Cichowski K. Epigenetic and oncogenic inhibitors cooperatively drive differentiation and kill KRAS-mutant colorectal cancers. Cancer Discov. 2024.
Lu Y, Travnickova J, Badonyi M, Rambow F, Coates A, Khan Z, Marques J, Murphy LC, Garcia-Martinez P, Marais R, Louphrasitthiphol P, Chan AHY, Schofield CJ, von Kriegsheim A, Marsh JA, Pavet V, Sansom OJ, Illingworth RS, Patton EE. ALDH1A3-acetaldehyde metabolism potentiates transcriptional heterogeneity in melanoma. Cell Rep. 2024;43(7):114406.
Malla SB, Byrne RM, Lafarge MW, Corry SM, Fisher NC, Tsantoulis PK, Mills ML, Ridgway RA, Lannagan TRM, Najumudeen AK, Gilroy KL, Amirkhah R, Maguire SL, Mulholland EJ, Belnoue-Davis HL, Grassi E, Viviani M, Rogan E, Redmond KL, Sakhnevych S, McCooey AJ, Bull C, Hoey E, Sinevici N, Hall H, Ahmaderaghi B, Domingo E, Blake A, Richman SD, Isella C, Miller C, Bertotti A, Trusolino L, Loughrey MB, Kerr EM, Tejpar S, Maughan TS, Lawler M, Campbell AD, Leedham SJ, Koelzer VH, Sansom OJ, Dunne PD. Pathway level subtyping identifies a slow-cycling biological phenotype associated with poor clinical outcomes in colorectal cancer. Nature Genetics. 2024.
Najumudeen AK, Fey SK, Millett LM, Ford CA, Gilroy K, Gunduz N, Ridgway RA, Anderson E, Strathdee D, Clark W, Nixon C, Morton JP, Campbell AD, Sansom OJ. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo. Nat Commun. 2024;15(1):100.
Nowak M, Jabbar F, Rodewald AK, Gneo L, Tomasevic T, Harkin A, Iveson T, Saunders M, Kerr R, Oein K, Maka N, Hay J, Edwards J, Tomlinson I, Sansom O, Kelly C, Pezzella F, Kerr D, Easton A, Domingo E, Koelzer VH, Church DN. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer. Cell Rep Med. 2024;5(9):101727.
Pennel KAF, Hatthakarnkul P, Wood CS, Lian GY, Al-Badran SSF, Quinn JA, Legrini A, Inthagard J, Alexander PG, van Wyk H, Kurniawan A, Hashmi U, Gillespie MA, Mills M, Ammar A, Hay J, Andersen D, Nixon C, Rebus S, Chang DK, Kelly C, Harkin A, Graham J, Church D, Tomlinson I, Saunders M, Iveson T, Lannagan TRM, Jackstadt R, Maka N, Horgan PG, Roxburgh CSD, Sansom OJ, McMillan DC, Steele CW, Jamieson NB, Park JH, Roseweir AK, Edwards J. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors. J Exp Clin Cancer Res. 2024;43(1):64.
Pereira BA, Ritchie S, Chambers CR, Gordon KA, Magenau A, Murphy KJ, Nobis M, Tyma VM, Liew YF, Lucas MC, Naeini MM, Barkauskas DS, Chacon-Fajardo D, Howell AE, Parker AL, Warren SC, Reed DA, Lee V, Metcalf XL, Lee YK, O'Regan LP, Zhu J, Trpceski M, Fontaine ARM, Stoehr J, Rouet R, Lin X, Chitty JL, Porazinski S, Wu SZ, Filipe EC, Cadell AL, Holliday H, Yang J, Papanicolaou M, Lyons RJ, Zaratzian A, Tayao M, Da Silva A, Vennin C, Yin J, Dew AB, McMillan PJ, Goldstein LD, Deveson IW, Croucher DR, Samuel MS, Sim HW, Batten M, Chantrill L, Grimmond SM, Gill AJ, Samra J, Jeffry Evans TR, Sasaki T, Phan TG, Swarbrick A, Sansom OJ, Morton JP, Pajic M, Parker BL, Herrmann D, Cox TR, Timpson P. Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response. Sci Adv. 2024;10(27):eadl1197.
Salvador-Barbero B, Alatsatianos M, Morton JP, Sansom OJ, Hogan C. Oncogenic KRAS cells use Wnt signalling and cell dormancy to override homeostatic cell elimination mechanisms in adult pancreas. bioRxiv. 2024:2024.2002.2013.579930.
Tesson M, Stevenson K, Karim SA, Nixon C, Chalmers AJ, Sansom OJ, O'Neil E, Jones K, Morton JP. Targeted irradiation in an autochthonous mouse model of pancreatic cancer. Dis Model Mech. 2024.
Whyte D, Voorde JV, Sumpton D, Dhayade S, Dornier E, Moore M, Novo D, Peters J, Wiesheu R, Mackey JBG, McFarlane AJ, Fercoq F, Fisher S, Caballero CD, Gilroy K, Redmond KL, Mitchell LE, Anderson E, Thomson G, Dzierozynski LN, Saab JJA, Lewis CA, Muir A, Halbrook CJ, Strathdee D, Jackstadt R, Nixon C, Dunne P, Steele CW, Carlin LM, Macpherson IR, Roberts EW, Coffelt SB, Blyth K, Sansom OJ, Norman JC, Clarke CJ. Uridine Phosphorylase-1 supports metastasis of mammary cancer by altering immune and extracellular matrix landscapes of the lung. bioRxiv. 2024:2024.2007.2002.601676.
Dannhorn A, Kazanc E, Flint L, Guo F, Carter A, Hall AR, Jones SA, Poulogiannis G, Barry ST, Sansom OJ, Bunch J, Takats Z, Goodwin RJA. Morphological and molecular preservation through universal preparation of fresh-frozen tissue samples for multimodal imaging workflows. Nat Protoc. 2024.
Sansom O, Wells S, Kent D, Wood A, Pitceathly RDS, Isles A, Liu K, Twigg S, Blyth K, Chesler L. Better translation via collaboration: The MRC National Mouse Genetics Network. Cell Genom. 2024 Feb 14;4(2):100483.
Nasreddin N, Sansom OJ. Host physiology shapes the mutational landscape of normal and carcinogenic tissue. Nat Genet. 2024.
2023
Amirkhah R, Gilroy K, Malla SB, Lannagan TRM, Byrne RM, Fisher NC, Corry SM, Mohamed N-E, Naderi-Meshkin H, Mills ML, Campbell AD, Ridgway RA, Ahmaderaghi B, Murray R, Llergo AB, Sanz-Pamplona R, Villanueva A, Batlle E, Salazar R, Lawler M, Sansom OJ, Dunne PD. MmCMS: mouse models’ consensus molecular subtypes of colorectal cancer. British Journal of Cancer. 2023;128: 1333–1343
Bailey P, Ridgway RA, Cammareri P, Treanor-Taylor M, Bailey UM, Schoenherr C, Bone M, Schreyer D, Purdie K, Thomson J, Rickaby W, Jackstadt R, Campbell AD, Dimonitsas E, Stratigos AJ, Arron ST, Wang J, Blyth K, Proby CM, Harwood CA, Sansom OJ, Leigh IM, Inman GJ. Driver gene combinations dictate cutaneous squamous cell carcinoma disease continuum progression. Nat Commun. 2023;14:5211.
Chen F, Gurler SB, Novo D, Selli C, Alferez DG, Eroglu S, Pavlou K, Zhang J, Sims AH, Humphreys NE, Adamson A, Campbell A, Sansom OJ, Tournier C, Clarke RB, Brennan K, Streuli CH, Ucar A. RAC1B function is essential for breast cancer stem cell maintenance and chemoresistance of breast tumor cells. Oncogene. 2023; 42: 679–692
Conway JRW, Warren SC, Lee YK, McCulloch AT, Magenau A, Lee V, Metcalf XL, Stoehr J, Haigh K, Abdulkhalek L, Guaman CS, Reed DA, Murphy KJ, Pereira BA, Mélénec P, Chambers C, Latham SL, Lenthall H, Deenick EK, Ma Y, Phan T, Lim E, Joshua AM, Walters S, Grey ST, Shi YC, Zhang L, Herzog H, Croucher DR, Philp A, Scheele C, Herrmann D, Sansom OJ, Morton JP, Papa A, Haigh JJ, Nobis M, Timpson P. Monitoring AKT activity and targeting in live tissue and disease contexts using a real-time Akt-FRET biosensor mouse. Sci Adv. 2023;9:eadf9063.
Fetit R, White M, Mills ML, Cortes-Lavaud X, McLaren A, Falconer J, Gilroy K, Nixon C, Kirschner K, Jackstadt R, Campbell AD, Sansom OJ, Steele CW. Characterising neutrophil subtypes in cancer using human and murine single-cell RNA sequencing datasets. bioRxiv. 2023;Volume:2023.2007.2013.548820.
Fey SK, Najumudeen AK, Ford C, Gilroy K, Upstill-Goddard R, Chang DK, Clark W, Nixon C, Barry ST, Morton JP, Campbell AD, Sansom OJ. Kras loss of heterozygosity promotes MAPK dependent pancreatic ductal adenocarcinoma and induces therapeutic sensitivity. bioRxiv. 2023:2023.2008.2029.552598.
Frei AL, McGuigan A, Sinha RR, Glaire MA, Jabbar F, Gneo L, Tomasevic T, Harkin A, Iveson TJ, Saunders M, Oein K, Maka N, Pezella F, Campo L, Hay J, Edwards J, Sansom OJ, Kelly C, Tomlinson I, Kildal W, Kerr RS, Kerr DJ, Danielsen HE, Domingo E, Church DN, Koelzer VH. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets. J Pathol Clin Res. 2023.
Holt AK, Najumudeen AK, Collard TJ, Li H, Millett LM, Hoskin AJ, Legge DN, Mortensson EMH, Flanagan DJ, Jones N, Kollareddy M, Timms P, Hitchings MD, Cronin J, Sansom OJ, Williams AC, Vincent EE. Aspirin reprogrammes colorectal cancer cell metabolism and sensitises to glutaminase inhibition. Cancer Metab. 2023;11(1):18.
Lu Y, Travnickova J, Badonyi M, Rambow F, Coates A, Khan Z, Marques J, Murphy L, Garcia-Martinez P, Marais R, Louphrasitthiphol P, Kriegsheim AV, Marsh JA, Pavet V, Sansom OJ, Illingworth R, Patton EE. ALDH1A3-acetaldehyde re-wires neural crest stem cell and high metabolism states to potentiate melanoma heterogeneity. bioRxiv. 2023:2023.2010.2028.564337.
Malik N, Hay J, Almuhanna HNB, Dunn KM, Lees J, Cassels J, Li J, Nakagawa R, Sansom OJ, Michie AM. mTORC1-selective activation of translation elongation promotes disease progression in chronic lymphocytic leukemia. Leukemia. 2023.
May S, Müller M, Livingstone CR, Skalka GL, Walsh PJ, Nixon C, Hedley A, Shaw R, Clark W, Voorde JV, Officer-Jones L, Ballantyne F, Powley IR, Drake TM, Kiourtis C, Keith A, Rocha AS, Tardito S, Sumpton D, Le Quesne J, Bushell M, Sansom OJ, Bird TG. Absent expansion of AXIN2+ hepatocytes and altered physiology in Axin2CreERT2 mice challenges the role of pericentral hepatocytes in homeostatic liver regeneration. J Hepatol. 2023; 78:1028-1036
Moore M, Pardo L, Mitchell L, Schmidt T, May S, Mueller M, Strathdee D, Bryson S, Hodge K, Lilla S, Zanivan S, Waldron J, McGarry L, Peter-Durairaj R, Kanellos G, Nixon C, Ballantyne F, LeQuesne J, Sansom OJ, Bird T, Bushell M, Norman JC. The eIF4A2 negative regulator of mRNA translation promotes extracellular matrix deposition to accelerate hepatocellular carcinoma initiation. bioRxiv. 2023;Volume:2023.2008.2016.553544.
Mzoughi S, Schwarz M, Wang X, Demircioglu D, Ulukaya G, Mohammed K, Tullio FD, Company C, Dramaretska Y, Leushacke M, Giotti B, Lannagan T, Lozano-Ojalvo D, Hasson D, Tsankov A, Sansom OJ, Marine J-C, Barker N, Gargiulo G, Guccione E. A Mutation-driven oncofetal regression fuels phenotypic plasticity in colorectal cancer. bioRxiv. 2023:2023.2012.2010.570854.
Perurena N, Lock R, Davis RA, Raghavan S, Pilla NF, Ng R, Loi P, Guild CJ, Miller AL, Sicinska E, Cleary JM, Rubinson DA, Wolpin BM, Gray NS, Santagata S, Hahn WC, Morton JP, Sansom OJ, Aguirre AJ, Cichowski K. USP9X mediates an acute adaptive response to MAPK suppression in pancreatic cancer but creates multiple actionable therapeutic vulnerabilities. Cell Rep Med. 2023;4:101007
Suzuki T, Kilbey A, Casa Rodriguez N, Lawlor A, Georgakopoulou A, Hayman H, Yin Swe KL, Nordin A, Cantù C, Vantourout P, Ridgway RA, Byrne RM, Chen L, Verzi MP, Gay DM, Gil Vazquez E, Belnoue-Davis HL, Gilroy K, Kostner AH, Kersten C, Thuwajit C, Andersen DK, Wiesheu R, Jandke A, Blyth K, Roseweir AK, Leedham SJ, Dunne PD, Edwards J, Hayday A, Sansom OJ, Coffelt SB. β-catenin drives butyrophilin-like molecule loss and γδ T-cell exclusion in colon cancer. Cancer Immunology Research. 2023;11:1137–1155
Vande Voorde J, Steven RT, Najumudeen AK, Ford CA, Dexter A, Gonzalez-Fernandez A, Nikula CJ, Xiang Y, Ford L, Maneta Stavrakaki S, Gilroy K, Zeiger LB, Pennel K, Hatthakarnkul P, Elia EA, Nasif A, Murta T, Manoli E, Mason S, Gillespie M, Lannagan TRM, Vlahov N, Ridgway RA, Nixon C, Raven A, Mills M, Athineos D, Kanellos G, Nourse C, Gay DM, Hughes M, Burton A, Yan B, Sellers K, Wu V, De Ridder K, Shokry E, Huerta Uribe A, Clark W, Clark G, Kirschner K, Thienpont B, Li VSW, Maddocks ODK, Barry ST, Goodwin RJA, Kinross J, Edwards J, Yuneva MO, Sumpton D, Takats Z, Campbell AD, Bunch J, Sansom OJ. Metabolic profiling stratifies colorectal cancer and reveals adenosylhomocysteinase as a therapeutic target. Nature Metabolism. 2023;10.1038/s42255-023-00857-0.
van Driel MS, Linssen JDG, Flanagan DJ, Vlahov N, Nijman LE, de Groot NE, Elbers CC, Koster J, Sansom OJ, Vermeulen L, van Neerven SM. Caffeine limits expansion of Apc-deficient clones in the intestine by NOTUM inhibition. Cell Mol Gastroenterol Hepatol. 2023;10.1016/j.jcmgh.2023.06.008.
Villar VH, Allega MF, Deshmukh R, Ackermann T, Nakasone MA, Vande Voorde J, Drake TM, Oetjen J, Bloom A, Nixon C, Müller M, May S, Tan EH, Vereecke L, Jans M, Blancke G, Murphy DJ, Huang DT, Lewis DY, Bird TG, Sansom OJ, Blyth K, Sumpton D, Tardito S. Hepatic glutamine synthetase controls N5-methylglutamine in homeostasis and cancer. Nature Chemical Biology. 2023;19:292-300.
Waldron JA, Kanellos G, Smith RCL, Knight JRP, Munro J, Alexandrou C, Vlahov N, Pardo-Fernandez L, Moore M, Gillen SL, Strathdee D, Stevenson D, Warrander FC, Gilroy K, Nixon C, Cadden B, Powley I, Officer-Jones L, Ballantyne F, Hay J, Pennel K, Edwards J, Campbell AD, Ridgway RA, Coffelt SB, Norman J, Quesne JL, Bushell M, Sansom OJ. eIF4A1 is essential for reprogramming the translational landscape of Wnt-driven colorectal cancers. bioRxiv. 2023:2023.2011.2010.566546.
Wood CS, Pennel KAF, Leslie H, Legrini A, Cameron AJ, Melissourgou-Syka L, Quinn JA, van Wyk HC, Hay J, Roseweir AK, Nixon C, Roxburgh CSD, McMillan DC, Biankin AV, Sansom OJ, Horgan PG, Edwards J, Steele CW, Jamieson NB. Spatially Resolved Transcriptomics Deconvolutes Prognostic Histological Subgroups in Patients with Colorectal Cancer and Synchronous Liver Metastases. Cancer Res. 2023;83:1329-1344.
2022
Ahmaderaghi B, Amirkhah R, Jackson J, Lannagan TRM, Gilroy K, Malla SB, Redmond KL, Quinn G, McDade S, Consortium A, Maughan T, Leedham S, Campbell AS, Sansom OJ, Lawler M, Dunne PD. The molecular subtyping resource (MouSR): a user-friendly tool for rapid biological discovery from transcriptional data. Dis Model Mech. 2022;15: dmm049257.
Ali A, Jamieson NB, Khan IN, Chang D, Giovannetti E, Funel N, Frampton AE, Morton J, Sansom O, Evans TRJ, Duthie F, McKay CJ, Samra J, Gill AJ, Biankin A, Oien KA. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. Am J Cancer Res. 2022;12:5668-5683.
Azkanaz M, Corominas-Murtra B, Ellenbroek SIJ, Bruens L, Webb AT, Laskaris D, Oost KC, Lafirenze SJA, Annusver K, Messal HA, Iqbal S, Flanagan DJ, Huels DJ, Rojas-Rodríguez F, Vizoso M, Kasper M, Sansom OJ, Snippert HJ, Liberali P, Simons BD, Katajisto P, Hannezo E, van Rheenen J. Retrograde movements determine effective stem cell numbers in the intestine. Nature. 2022;607:548-554.
Cook DR, Kang M, Martin TD, Galanko JA, Loeza GH, Trembath DG, Justilien V, Pickering KA, Vincent DF, Jarosch A, Jurmeister P, Waters AM, Hibshman PS, Campbell AD, Ford CA, Keku TO, Yeh JJ, Lee MS, Cox AD, Fields AP, Sandler RS, Sansom OJ, Sers C, Schaefer A, Der CJ. Aberrant expression and subcellular localization of ECT2 drives colorectal cancer progression and growth. Cancer Res. 2022; 82:90-104
Corry SM, McCorry AM, Lannagan TR, Leonard NA, Fisher NC, Byrne RM, Tsantoulis P, Cortes-Lavaud X, Amirkhah R, Redmond KL, McCooey AJ, Malla SB, Rogan E, Sakhnevych S, Gillespie MA, White M, Richman SD, Jackstadt RF, Campbell AD, Maguire S, McDade SS, Longley 1137–1155DB, Loughrey MB, Coleman HG, Kerr EM, Tejpar S, Maughan T, Leedham SJ, Small DM, Ryan AE, Sansom OJ, Lawler M, Dunne PD. Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer. Gut. 2022;71:2502-2517
Fisher NC, Byrne RM, Leslie H, Wood C, Legrini A, Cameron AJ, Ahmaderaghi B, Corry SM, Malla SB, Amirkhah R, McCooey AJ, Rogan E, Redmond KL, Sakhnevych S, Domingo E, Jackson J, Loughrey MB, Leedham S, Maughan T, Lawler M, Sansom OJ, Lamrock F, Koelzer VH, Jamieson NB, Dunne PD. Biological Misinterpretation of Transcriptional Signatures in Tumor Samples can Unknowingly Undermine Mechanistic Understanding and Faithful Alignment with Preclinical Data. Clinical Cancer Research. 2022;10.1158/1078-0432.Ccr-22-1102:OF1-OF14.
Flanagan DJ, Amirkhah R, Vincent DF, Gundaz N, Gentaz P, Cammareri P, McCooey AJ, McCorry AMB, Fisher NC, Davis HL, Ridgway RA, Lohuis J, Leach JDG, Jackstadt R, Gilroy K, Mariella E, Nixon C, Clark W, Hedley A, Markert EK, Strathdee D, Bartholin L, Redmond KL, Kerr EM, Longley DB, Ginty F, Cho S, Coleman HG, Loughrey MB, Bardelli A, Maughan TS, Campbell AD, Lawler M, Leedham SJ, Barry ST, Inman GJ, van Rheenen J, Dunne PD, Sansom OJ. Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nat Commun. 2022;13:7551.
Freckmann EC, Sandilands E, Cumming E, Neilson M, Román-Fernández A, Nikolatou K, Nacke M, Lannagan TRM, Hedley A, Strachan D, Salji M, Morton JP, McGarry L, Leung HY, Sansom OJ, Miller CJ, Bryant DM. Traject3d allows label-free identification of distinct co-occurring phenotypes within 3D culture by live imaging. Nat Commun. 2022;13:5317.
Gil Vasquez E, Nasreddin N, Valbuena GN, Mulholland EJ, Belnoue-Davis HL, Eggington H, Schenck RO, Wouters VM, Wirapati P, Gilroy K, Lannagan TRM, Flanagan DJ, Najumudeen AK, Omwenga S, McCorry AMB, Easton A, Koelzer VH, East JE, Morton D, Trusolino L, Maughan T, Campbell AD, Loughrey MB, Dunne PD, Tsantoulis P, Huels DJ, Tejpar S, Sansom O, Leedham SJ. Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture. bioRxiv. 2022;Volume:2022.2006.2011.495729.
Hedayioglu F, Mead EJ, O'Connor PBF, Skiotys M, Sansom OJ, Mallucci GR, Willis AE, Baranov PV, Smales CM, von der Haar T. Evaluating data integrity in ribosome footprinting datasets through modelled polysome profiles. Nucleic Acids Res. 2022;50:e112
Kidger AM, Saville MK, Rushworth LK, Davidson J, Stellzig J, Ono M, Kuebelsbeck LA, Janssen KP, Holzmann B, Morton JP, Sansom OJ, Caunt CJ, Keyse SM. Suppression of mutant Kirsten-RAS (KRAS(G12D))-driven pancreatic carcinogenesis by dual-specificity MAP kinase phosphatases 5 and 6. Oncogene. 2022;41:2811–2823
Knight JRP, Proud CG, Mallucci G, Haar TV, Smales CM, Willis AE, Sansom OJ. eEF2K activity is required for the phenotypes of the Rpl24(Bst) mouse. J Invest Dermatol. 2022;142:3346-3348.e1
Leslie J, Mackey JBG, Jamieson T, Ramon-Gil E, Drake TM, Fercoq F, Clark W, Gilroy K, Hedley A, Nixon C, Luli S, Laszczewska M, Pinyol R, Esteban-Fabró R, Willoughby CE, Haber PK, Andreu-Oller C, Rahbari M, Fan C, Pfister D, Raman S, Wilson N, Müller M, Collins A, Geh D, Fuller A, McDonald D, Hulme G, Filby A, Cortes-Lavaud X, Mohamed N-E, Ford CA, Raffo Iraolagoitia XL, McFarlane AJ, McCain MV, Ridgway RA, Roberts EW, Barry ST, Graham GJ, Heikenwälder M, Reeves HL, Llovet JM, Carlin LM, Bird TG, Sansom OJ, Mann DA. CXCR2 inhibition enables NASH-HCC immunotherapy. Gut. 2022; 71:2093-2106
Malik N, Hay J, Dunn KM, Nakagawa R, Sansom OJ, Michie AM. mTORC1 activity is essential for disease progression in chronic lymphocytic leukemia. bioRxiv; 10.1101/2022.04.19.4887782022:2022.2004.2019.488778.
May S, Greenow KR, Higgins AT, Derrick AV, Taylor E, Pan P, Konstantinou M, Nixon C, Wooley TE, Sansom OJ, Wang LS, Parry L. Modification of Diet to Reduce the Stemness and Tumorigenicity of Murine and Human Intestinal Cells. Mol Nutr Food Res. 2022;66:2200234
Parker C, Chambers AC, Flanagan DJ, Ho JWY, Collard TJ, Ngo G, Baird DM, Timms P, Morgan RG, Sansom OJ, Williams AC. BCL-3 loss sensitises colorectal cancer cells to DNA damage by targeting homologous recombination. DNA Repair (Amst). 2022;115:103331.
Patel R, Ford CA, Rodgers L, Rushworth LK, Fleming J, Mui E, Zhang T, Watson D, Lynch V, Mackay G, Sumpton D, Sansom OJ, Vande Voorde J, Leung HY. Cyclocreatine suppresses creatine metabolism and impairs prostate cancer progression. Cancer Res. 2022;82: 2565–2575
Ramadan R, Wouters VM, van Neerven SM, de Groot NE, Martins GT, Muncan V, Franklin OD, Battle M, Carlson KS, Leach J, Sansom OJ, Boulard O, Chamaillard M, Vermeulen L, Medema JP, Huels DJ. The extracellular matrix controls stem cell specification and crypt morphology in the developing and adult mouse gut. Biol Open. 2022;11:bio059544
Strittmatter N, Richards FM, Race AM, Ling S, Sutton D, Nilsson A, Wallez Y, Barnes J, Maglennon G, Gopinathan A, Brais R, Wong E, Serra MP, Atkinson J, Smith A, Wilson J, Hamm G, Johnson TI, Dunlop CR, Kaistha BP, Bunch J, Sansom OJ, Takats Z, Andrén PE, Lau A, Barry ST, Goodwin RJA, Jodrell DI. Method To Visualize the Intratumor Distribution and Impact of Gemcitabine in Pancreatic Ductal Adenocarcinoma by Multimodal Imaging. Anal Chem. 2022;94:1795–1803
Vasquez EG, Nasreddin N, Valbuena GN, Mulholland EJ, Belnoue-Davis HL, Eggington HR, Schenck RO, Wouters VM, Wirapati P, Gilroy K, Lannagan TRM, Flanagan DJ, Najumudeen AK, Omwenga S, McCorry AMB, Easton A, Koelzer VH, East JE, Morton D, Trusolino L, Maughan T, Campbell AD, Loughrey MB, Dunne PD, Tsantoulis P, Huels DJ, Tejpar S, Sansom OJ, Leedham SJ. Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia. Cell Stem Cell. 2022;29:1213-1228.e1218.
Walter RJ, Sonnentag SJ, Munoz-Sagredo L, Merkel M, Richert L, Bunert F, Heneka YM, Loustau T, Hodder M, Ridgway RA, Sansom OJ, Mely Y, Rothbauer U, Schmitt M, Orian-Rousseau V. Wnt signaling is boosted during intestinal regeneration by a CD44-positive feedback loop. Cell Death Dis. 2022;13:168.
Bristow RG, Engel J, Jayasinghe I, Kampmann M, James Sansom O, Bryant DM. Conversations with LGBT+ scientists about visibility, leadership and climbing the career ladder. Journal of Cell Science. 2022;135.
Flanagan DJ, Woodcock SA, Phillips C, Eagle C, Sansom OJ. Targeting ligand-dependent wnt pathway dysregulation in gastrointestinal cancers through porcupine inhibition. Pharmacol Ther. 2022:108179.
Sansom O. A new network for the synergistic translation of mouse research. Dis Model Mech. 2022;15:dmm049865
2021
Alexander PG, Roseweir AK, Pennel KAF, van Wyk HC, Powell A, McMillan DC, Horgan PG, Kelly C, Hay J, Sansom O, Harkin A, Roxburgh CSD, Graham J, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J, Park JH. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer. Br J Cancer. 2021;124:786-796.
Dreyer SB, Upstill-Goddard R, Paulus-Hock V, Paris C, Lampraki EM, Dray E, Serrels B, Caligiuri G, Rebus S, Plenker D, Galluzzo Z, Brunton H, Cunningham R, Tesson M, Nourse C, Bailey UM, Jones M, Moran-Jones K, Wright DW, Duthie F, Oien K, Evers L, McKay CJ, McGregor GA, Gulati A, Brough R, Bajrami I, Pettitt S, Dziubinski ML, Candido J, Balkwill F, Barry ST, Grützmann R, Rahib L, Johns A, Pajic M, Froeling FEM, Beer P, Musgrove EA, Petersen GM, Ashworth A, Frame MC, Crawford HC, Simeone DM, Lord C, Mukhopadhyay D, Pilarsky C, Tuveson DA, Cooke SL, Jamieson NB, Morton JP, Sansom OJ, Bailey PJ, Biankin AV, Chang DK. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Gastroenterology. 2021;160(1):362-377.e313.
Dunbar K, Valanciute A, Lima ACS, Vinuela PF, Jamieson T, Rajasekaran V, Blackmur J, Ochocka-Fox AM, Guazzelli A, Cammareri P, Arends MJ, Sansom OJ, Myant KB, Farrington SM, Dunlop MG, Din FVN. Aspirin Rescues Wnt-Driven Stem-like Phenotype in Human Intestinal Organoids and Increases the Wnt Antagonist Dickkopf-1. Cell Mol Gastroenterol Hepatol. 2021;11(2):465-489.
Falcomata C, Barthel S, Ulrich A, Diersch S, Veltkamp C, Rad L, Boniolo F, Solar M, Steiger K, Seidler B, Zukowska M, Madej J, Wang M, Ollinger R, Maresch R, Barenboim M, Eser S, Tschurtschenthaler M, Mehrabi A, Roessler S, Goeppert B, Kind A, Schnieke A, Robles MS, Bradley A, Schmid RM, Schmidt-Supprian M, Reichert M, Weichert W, Sansom OJ, Morton JP, Rad R, Schneider G, Saur D. Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer. Cancer Discov. 2021;11:3158–3177
Flanagan DJ, Pentinmikko N, Luopajärvi K, Willis NJ, Gilroy K, Raven AP, McGarry L, Englund JI, Webb AT, Scharaw S, Nasreddin N, Hodder MC, Ridgway RA, Minnee E, Sphyris N, Gilchrist E, Najumudeen AK, Romagnolo B, Perret C, Williams AC, Clevers H, Nummela P, Lähde M, Alitalo K, Hietakangas V, Hedley A, Clark W, Nixon C, Kirschner K, Jones EY, Ristimäki A, Leedham SJ, Fish PV, Vincent JP, Katajisto P, Sansom OJ. NOTUM from Apc-mutant cells biases clonal competition to initiate cancer. Nature. 2021;594(7863):430-435.
Floerchinger A, Murphy KJ, Latham SL, Warren SC, McCulloch AT, Lee YK, Stoehr J, Mélénec P, Guaman CS, Metcalf XL, Lee V, Zaratzian A, Da Silva A, Tayao M, Rolo S, Phimmachanh M, Sultani G, McDonald L, Mason SM, Ferrari N, Ooms LM, Johnsson AE, Spence HJ, Olson MF, Machesky LM, Sansom OJ, Morton JP, Mitchell CA, Samuel MS, Croucher DR, Welch HCE, Blyth K, Caldon CE, Herrmann D, Anderson KI, Timpson P, Nobis M. Optimizing metastatic-cascade-dependent Rac1 targeting in breast cancer: Guidance using optical window intravital FRET imaging. Cell Rep. 2021;36(11):109689.
Galbraith LCA, Mui E, Nixon C, Hedley A, Strachan D, MacKay G, Sumpton D, Sansom OJ, Leung HY, Ahmad I. PPAR-gamma induced AKT3 expression increases levels of mitochondrial biogenesis driving prostate cancer. Oncogene. 2021;40:2355-2366.
Grosso S, Marini A, Gyuraszova K, Voorde JV, Sfakianos A, Garland GD, Tenor AR, Mordue R, Chernova T, Morone N, Sereno M, Smith CP, Officer L, Farahmand P, Rooney C, Sumpton D, Das M, Teodósio A, Ficken C, Martin MG, Spriggs RV, Sun XM, Bushell M, Sansom OJ, Murphy D, MacFarlane M, Le Quesne JPC, Willis AE. The pathogenesis of mesothelioma is driven by a dysregulated translatome. Nat Commun. 2021;12:4920.
Gudiño V, Pohl S, Billard CV, Cammareri P, Bolado A, Aitken S, Stevenson D, Hall AE, Agostino M, Cassidy J, Nixon C, von Kriegsheim A, Freile P, Popplewell L, Dickson G, Murphy L, Wheeler A, Dunlop M, Din F, Strathdee D, Sansom OJ, Myant KB. RAC1B modulates intestinal tumourigenesis via modulation of WNT and EGFR signalling pathways. Nat Commun. 2021;12:2335.
Guillermin O, Angelis N, Sidor CM, Ridgway R, Baulies A, Kucharska A, Antas P, Rose MR, Cordero J, Sansom O, Li VSW, Thompson BJ. Wnt and Src signals converge on YAP-TEAD to drive intestinal regeneration. Embo j. 2021:e105770.
Heino S, Fang S, Lähde M, Högström J, Nassiri S, Campbell A, Flanagan D, Raven A, Hodder M, Nasreddin N, Xue HH, Delorenzi M, Leedham S, Petrova TV, Sansom O, Alitalo K. Lef1 restricts ectopic crypt formation and tumor cell growth in intestinal adenomas. Sci Adv. 2021;7(47):eabj0512.
Hill W, Zaragkoulias A, Salvador-Barbero B, Parfitt GJ, Alatsatianos M, Padilha A, Porazinski S, Woolley TE, Morton JP, Sansom OJ, Hogan C. EPHA2-dependent outcompetition of KRASG12D mutant cells by wild-type neighbors in the adult pancreas. Curr Biol. 2021;31:2550-2560.e5
Hutton C, Heider F, Blanco-Gomez A, Banyard A, Kononov A, Zhang X, Karim S, Paulus-Hock V, Watt D, Steele N, Kemp S, Hogg EKJ, Kelly J, Jackstadt RF, Lopes F, Menotti M, Chisholm L, Lamarca A, Valle J, Sansom OJ, Springer C, Malliri A, Marais R, Pasca di Magliano M, Zelenay S, Morton JP, Jørgensen C. Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity. Cancer Cell. 2021; 39: 1227-1244.e20
Knight JRP, Alexandrou C, Skalka GL, Vlahov N, Pennel K, Officer L, Teodosio A, Kanellos G, Gay DM, May-Wilson S, Smith EM, Najumudeen AK, Gilroy K, Ridgway RA, Flanagan DJ, Smith RCL, McDonald L, MacKay C, Cheasty A, McArthur K, Stanway E, Leach JD, Jackstadt R, Waldron JA, Campbell AD, Vlachogiannis G, Valeri N, Haigis KM, Sonenberg N, Proud CG, Jones NP, Swarbrick ME, McKinnon HJ, Faller WJ, Le Quesne J, Edwards J, Willis AE, Bushell M, Sansom OJ. MNK Inhibition Sensitizes KRAS-Mutant Colorectal Cancer to mTORC1 Inhibition by Reducing eIF4E Phosphorylation and c-MYC Expression. Cancer Discov. 2021;11(5):1228-1247.
Knight JR, Vlahov N, Gay DM, Ridgway RA, Faller WJ, Proud C, Mallucci GR, von der Haar T, Smales CM, Willis AE, Sansom OJ. Rpl24(Bst) mutation suppresses colorectal cancer by promoting eEF2 phosphorylation via eEF2K. Elife. 2021;10:e69729
Krotenberg Garcia A, Fumagalli A, Le HQ, Jackstadt R, Lannagan TRM, Sansom OJ, van Rheenen J, Suijkerbuijk SJE. Active elimination of intestinal cells drives oncogenic growth in organoids. Cell Rep. 2021;36:109307.
Lähde M, Heino S, Högström J, Kaijalainen S, Anisimov A, Flanagan D, Kallio P, Leppänen VM, Ristimäki A, Ritvos O, Wu K, Tammela T, Hodder M, Sansom OJ, Alitalo K. Expression of R-Spondin 1 in Apc(Min/+) Mice Suppresses Growth of Intestinal Adenomas by Altering Wnt and Transforming Growth Factor Beta Signaling. Gastroenterology. 2021;160(1):245-259.
Lampis A, Hahne JC, Gasparini P, Cascione L, Hedayat S, Vlachogiannis G, Murgia C, Fontana E, Edwards J, Horgan PG, Terracciano L, Sansom OJ, Martins CD, Kramer-Marek G, Croce CM, Braconi C, Fassan M, Valeri N. MIR21-induced loss of junctional adhesion molecule A promotes activation of oncogenic pathways, progression and metastasis in colorectal cancer. Cell Death Differ. 2021; 28: 2970–2982
Leach JDG, Vlahov N, Tsantoulis P, Ridgway RA, Flanagan DJ, Gilroy K, Sphyris N, Vázquez EG, Vincent DF, Faller WJ, Hodder MC, Raven A, Fey S, Najumudeen AK, Strathdee D, Nixon C, Hughes M, Clark W, Shaw R, van Hooff SR, Huels DJ, Medema JP, Barry ST, Frame MC, Unciti-Broceta A, Leedham SJ, Inman GJ, Jackstadt R, Thompson BJ, Campbell AD, Tejpar S, Sansom OJ. Oncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis. Nat Commun. 2021;12:3464.
Mackey JBG, McFarlane AJ, Jamieson T, Jackstadt R, Raffo-Iraolagoitia XL, Secklehner J, Cortes-Lavaud X, Fercoq F, Clarke W, Hedley A, Gilroy K, Lilla S, Vuononvirta J, Graham GJ, De Filippo K, Murphy DJ, Steele CW, Norman JC, Bird TG, Mann DA, Morton JP, Zanivan S, Sansom OJ, Carlin LM. Maturation, developmental site, and pathology dictate murine neutrophil function. bioRxiv. 2021.
Minnis-Lyons SE, Ferreira-González S, Aleksieva N, Man TY, Gadd VL, Williams MJ, Guest RV, Lu WY, Dwyer BJ, Jamieson T, Nixon C, Van Hul N, Lemaigre FP, McCafferty J, Leclercq IA, Sansom OJ, Boulter L, Forbes SJ. Notch-IGF1 signaling during liver regeneration drives biliary epithelial cell expansion and inhibits hepatocyte differentiation. Sci Signal. 2021;14:eaay9185
Murphy KJ, Reed DA, Vennin C, Conway JRW, Nobis M, Yin JX, Chambers CR, Pereira BA, Lee V, Filipe EC, Trpceski M, Ritchie S, Lucas MC, Warren SC, Skhinas JN, Magenau A, Metcalf XL, Stoehr J, Major G, Parkin A, Bidanel R, Lyons RJ, Zaratzian A, Tayao M, Da Silva A, Abdulkhalek L, Gill AJ, Johns AL, Biankin AV, Samra J, Grimmond SM, Chou A, Goetz JG, Samuel MS, Lyons JG, Burgess A, Caldon CE, Horvath LG, Daly RJ, Gadegaard N, Wang Y, Sansom OJ, Morton JP, Cox TR, Pajic M, Herrmann D, Timpson P. Intravital imaging technology guides FAK-mediated priming in pancreatic cancer precision medicine according to Merlin status. Sci Adv. 2021;7:eabh0363.
Murta T, Steven RT, Nikula CJ, Thomas SA, Zeiger LB, Dexter A, Elia EA, Yan B, Campbell AD, Goodwin RJA, Takáts Z, Sansom OJ, Bunch J. Implications of Peak Selection in the Interpretation of Unsupervised Mass Spectrometry Imaging Data Analyses. Anal Chem. 2021; 93: 2309–2316
Najumudeen AK, Ceteci F, Fey SK, Hamm G, Steven RT, Hall H, Nikula CJ, Dexter A, Murta T, Race AM, Sumpton D, Vlahov N, Gay DM, Knight JRP, Jackstadt R, Leach JDG, Ridgway RA, Johnson ER, Nixon C, Hedley A, et al. The amino acid transporter SLC7A5 is required for efficient growth of KRAS-mutant colorectal cancer. Nat Genet. 2021;53:16-26.
Nászai M, Bellec K, Yu Y, Román-Fernández A, Sandilands E, Johansson J, Campbell AD, Norman JC, Sansom OJ, Bryant DM, Cordero JB. RAL GTPases mediate EGFR-driven intestinal stem cell proliferation and tumourigenesis. Elife. 2021;10:e63807
Nielsen SR, Strøbech JE, Horton ER, Jackstadt R, Laitala A, Bravo MC, Maltese G, Jensen ARD, Reuten R, Rafaeva M, Karim SA, Hwang CI, Arnes L, Tuveson DA, Sansom OJ, Morton JP, Erler JT. Suppression of tumor-associated neutrophils by lorlatinib attenuates pancreatic cancer growth and improves treatment with immune checkpoint blockade. Nat Commun. 2021;12(1):3414.
O'Connor MN, Kallenberg DM, Camilli C, Pilotti C, Dritsoula A, Jackstadt R, Bowers CE, Watson HA, Alatsatianos M, Ohme J, Dowsett L, George J, Blackburn JWD, Wang X, Singhal M, Augustin HG, Ager A, Sansom OJ, Moss SE, Greenwood J. LRG1 destabilizes tumor vessels and restricts immunotherapeutic potency. Med (N Y). 2021;2:1231-1252.e1210.
Pickering KA, Gilroy K, Cassidy JW, Fey SK, Najumudeen AK, Zeiger LB, Vincent DF, Gay DM, Johansson J, Fordham RP, Miller B, Clark W, Hedley A, Unal EB, Kiel C, McGhee E, Machesky LM, Nixon C, Johnsson AE, Bain M, et al. A RAC-GEF network critical for early intestinal tumourigenesis. Nat Commun. 2021;12:56.
Race AM, Sutton D, Hamm G, Maglennon G, Morton JP, Strittmatter N, Campbell A, Sansom OJ, Wang Y, Barry ST, Takáts Z, Goodwin RJA, Bunch J. Deep Learning-Based Annotation Transfer between Molecular Imaging Modalities: An Automated Workflow for Multimodal Data Integration. Anal Chem. 2021;93(6):3061-3071.
Ramesh P, Lannagan TRM, Jackstadt R, Atencia Taboada L, Lansu N, Wirapati P, van Hooff SR, Dekker D, Pritchard J, Kirov AB, van Neerven SM, Tejpar S, Kops G, Sansom OJ, Medema JP. BCL-XL is crucial for progression through the adenoma-to-carcinoma sequence of colorectal cancer. Cell Death Differ. 2021;28:3282–3296
Sacchetti A, Teeuwssen M, Verhagen M, Joosten R, Xu T, Stabile R, van der Steen B, Watson MM, Gusinac A, Kim WK, Ubink I, Van de Werken HJ, Fumagalli A, Paauwe M, Van Rheenen J, Sansom OJ, Kranenburg O, Fodde R. Phenotypic plasticity underlies local invasion and distant metastasis in colon cancer. Elife. 2021;10:61461
Sharbeen G, McCarroll JA, Akerman A, Kopecky C, Youkhana J, Kokkinos J, Holst J, Boyer C, Erkan M, Goldstein D, Timpson P, Cox TR, Pereira BA, Chitty JL, Fey SK, Najumudeen AK, Campbell AD, Sansom OJ, Ignacio RMC, Naim S, Liu J, Russia N, Lee J, Chou A, Johns A, Gill AJ, Gonzales-Aloy E, Gebski V, Guan YF, Pajic M, Turner N, Apte MV, Davis TP, Morton JP, Haghighi KS, Kasparian J, McLean BJ, Setargew YFI, Apgi A, Phillips PA. Cancer-associated fibroblasts in pancreatic ductal adenocarcinoma determine response to SLC7A11 inhibition. Cancer Res. 2021; 81: 3461-3479
Swaminathan K, Campbell A, Papalazarou V, Jaber-Hijazi F, Nixon C, McGhee E, Strathdee D, Sansom OJ, Machesky LM. The RAC1 Target NCKAP1 Plays a Crucial Role in the Progression of Braf;Pten-Driven Melanoma in Mice. J Invest Dermatol. 2021;141(3):628-637.e615.
Tajan M, Hennequart M, Cheung EC, Zani F, Hock AK, Legrave N, Maddocks ODK, Ridgway RA, Athineos D, Suárez-Bonnet A, Ludwig RL, Novellasdemunt L, Angelis N, Li VSW, Vlachogiannis G, Valeri N, Mainolfi N, Suri V, Friedman A, Manfredi M, et al. Serine synthesis pathway inhibition cooperates with dietary serine and glycine limitation for cancer therapy. Nat Commun. 2021;12:366.
van der Weyden L, Harle V, Turner G, Offord V, Iyer V, Droop A, Swiatkowska A, Rabbie R, Campbell AD, Sansom OJ, Pardo M, Choudhary JS, Ferreira I, Tullett M, Arends MJ, Speak AO, Adams DJ. CRISPR activation screen in mice identifies novel membrane proteins enhancing pulmonary metastatic colonisation. Commun Biol. 2021;4(1):395.
Gillespie MA, Steele CW, Lannagan TRM, Sansom OJ, Roxburgh CSD. Pre-clinical modelling of rectal cancer to develop novel radiotherapy-based treatment strategies. Oncol Rev. 2021;15:511.
Knight JRP, Sansom OJ. Tuning protein synthesis for cancer therapy. Mol Cell Oncol. 2021;8:1884034.
Lannagan TR, Jackstadt R, Leedham SJ, Sansom OJ. Advances in colon cancer research: in vitro and animal models. Curr Opin Genet Dev. 2021;66:50-56.
Rosenfeldt MT, O'Prey J, Lindsay CR, Nixon C, Roth S, Sansom OJ, Ryan KM. Loss of autophagy affects melanoma development in a manner dependent on PTEN status. Cell Death Differ. 2021;28:1437-1439.
Smith RCL, Kanellos G, Vlahov N, Alexandrou C, Willis AE, Knight JRP, Sansom OJ. Translation initiation in cancer at a glance. J Cell Sci. 2021;134:jcs248476.
Sphyris N, Hodder MC, Sansom OJ. Subversion of Niche-Signalling Pathways in Colorectal Cancer: What Makes and Breaks the Intestinal Stem Cell. Cancers (Basel). 2021;13:1000
2020
Bruens L, Ellenbroek SIJ, Suijkerbuijk SJE, Azkanaz M, Hale AJ, Toonen P, Flanagan DJ, Sansom OJ, Snippert HJ, van Rheenen J. Calorie Restriction Increases the Number of Competing Stem Cells and Decreases Mutation Retention in the Intestin e. Cell Rep. 2020;32(3):107937.
Brunton H, Caligiuri G, Cunningham R, Upstill-Goddard R, Bailey UM, Garner IM, Nourse C, Dreyer S, Jones M, Moran-Jones K, Wright DW, Paulus-Hock V, Nixon C, Thomson G, Jamieson NB, McGregor GA, Evers L, McKay CJ, Gulati A, Brough R, Bajrami I, Pettitt SJ, Dziubinski ML, Barry ST, Grützmann R, Brown R, Curry E, Pajic M, Musgrove EA, Petersen GM, Shanks E, Ashworth A, Crawford HC, Simeone DM, Froeling FEM, Lord CJ, Mukhopadhyay D, Pilarsky C, Grimmond SE, Morton JP, Sansom OJ, Chang DK, Bailey PJ, Biankin AV. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Cell Rep. 2020;31:107625
Dannhorn A, Kazanc E, Ling S, Nikula C, Karali E, Serra MP, Vorng JL, Inglese P, Maglennon G, Hamm G, Swales J, Strittmatter N, Barry ST, Sansom OJ, Poulogiannis G, Bunch J, Goodwin RJ, Takats Z. Universal Sample Preparation Unlocking Multimodal Molecular Tissue Imaging. Anal Chem. 2020;92(16):11080-11088.
Dreyer SB, Jamieson NB, Morton JP, Sansom OJ, Biankin AV, Chang DK. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. Clinical oncology (Royal College of Radiologists (Great Britain)). 2020; 32: 5–8
Healy ME, Boege Y, Hodder MC, Böhm F, Malehmir M, Scherr AL, Jetzer J, Chan LK, Parrotta R, Jacob K, Clerbaux LA, Kreutzer S, Campbell A, Gilchrist E, Gilroy K, Rodewald AK, Honcharova-Biletska H, Schimmer R, Vélez K, Büeler S, Cammareri P, Kalna G, Wenning AS, McCoy KD, Gomez de Agüero M, Schulze-Bergkamen H, Klose C, Unger K, Macpherson AJ, Moor AE, Köhler B, Sansom OJ, Heikenwalder M, Weber A. MCL1 is Required for Maintenance of Intestinal Homeostasis and Prevention of Carcinogenesis in Mice. Gastroenterology. 2020; 159: 183-199
Kaymak I, Maier CR, Schmitz W, Campbell AD, Dankworth B, Ade CP, Walz S, Paauwe M, Kalogirou C, Marouf H, Rosenfeldt MT, Gay DM, McGregor GH, Sansom OJ, Schulze A. Mevalonate pathway provides ubiquinone to maintain pyrimidine synthesis and survival in p53-deficient cancer cells exposed to metabolic stress. Cancer research. 2020; 80:189–203
Kennedy SA, Jarboui MA, Srihari S, Raso C, Bryan K, Dernayka L, Charitou T, Bernal-Llinares M, Herrera-Montavez C, Krstic A, Matallanas D, Kotlyar M, Jurisica I, Curak J, Wong V, Stagljar I, LeBihan T, Imrie L, Pillai P, Lynn MA, Fasterius E, Al-Khalili Szigyarto C, Breen J, Kiel C, Serrano L, Rauch N, Rukhlenko O, Kholodenko BN, Iglesias-Martinez LF, Ryan CJ, Pilkington R, Cammareri P, Sansom O, Shave S, Auer M, Horn N, Klose F, Ueffing M, Boldt K, Lynn DJ, Kolch W. Extensive rewiring of the EGFR network in colorectal cancer cells expressing transforming levels of KRAS(G13D). Nature communications. 2020; 11: 499.
Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S. RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer. Cell Death Dis. 2020 Oct 29;11(10):930
Knight JRP, Garland G, Pöyry T, Mead E, Vlahov N, Sfakianos A, Grosso S, De-Lima-Hedayioglu F, Mallucci GR, von der Haar T, Smales CM, Sansom OJ, Willis AE. Control of translation elongation in health and disease. Disease Models & Mechanisms. 2020; 13: dmm043208.
Maniati E, Berlato C, Gopinathan G, Heath O, Kotantaki P, Lakhani A, McDermott J, Pegrum C, Delaine-Smith RM, Pearce OMT, Hirani P, Joy JD, Szabova L, Perets R, Sansom OJ, Drapkin R, Bailey P, Balkwill FR. Mouse Ovarian Cancer Models Recapitulate the Human Tumor Microenvironment and Patient Response to Treatment. Cell reports. 2020; 30: 525-540.e527.
McGregor GH, Campbell AD, Fey SK, Tumanov S, Sumpton D, Rodriguez Blanco G, Mackay G, Nixon C, Vazquez A, Sansom OJ, Kamphorst JJ. Targeting the metabolic response to statin-mediated oxidative stress produces a synergistic anti-tumor response. Cancer research. 2020; 80:175–88
Michalopoulou E, Auciello FR, Bulusu V, Strachan D, Campbell AD, Tait-Mulder J, Karim SA, Morton JP, Sansom OJ, Kamphorst JJ. Macropinocytosis Renders a Subset of Pancreatic Tumor Cells Resistant to mTOR Inhibition. Cell reports. 2020;30:2729-2742.e2724.
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, Laing S, Kruspig B, Upstill-Goddard R, Shaw R, Neidler S, Rink C, Karim SA, Gyuraszova K, Nixon C, Clark W, Biankin AV, Carlin LM, Coffelt SB, Sansom OJ, Morton JP, Murphy DJ. Repression of the Type I Interferon pathway underlies MYC & KRAS-dependent evasion of NK & B cells in Pancreatic Ductal Adenocarcinoma. Cancer discovery. 2020; 10:872-887
Patel R, Brzezinska EA, Repiscak P, Ahmad I, Mui E, Gao M, Blomme A, Harle V, Tan EH, Malviya G, Mrowinska A, Loveridge CJ, Rushworth LK, Edwards J, Ntala C, Nixon C, Hedley A, Mackay G, Tardito S, Sansom OJ, Leung HY. Activation of beta-catenin cooperates with loss of Pten to drive AR-independent castration-resistant prostate cancer. Cancer research. 2020; 80:576–90
Rooney N, Mason SM, McDonald L, Däbritz JHM, Campbell KJ, Hedley A, Howard S, Athineos D, Nixon C, Clark W, Leach JDG, Sansom OJ, Edwards J, Cameron ER, Blyth K RUNX1 is a driver of renal cell carcinoma correlating with clinical outcome Cancer Res. 2020; 80: 2325-2339
Roseweir AK, Park JH, Hoorn ST, Powell AG, Aherne S, Roxburgh CS, McMillan DC, Horgan PG, Ryan E, Sheahan K, Vermeulen L, Paul J, Harkin A, Graham J, Sansom O, Church DN, Tomlinson I, Saunders M, Iveson TJ, Edwards J. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer. J Path Clin Res. 2020; 6: 283-296
Smith ALM, Whitehall JC, Bradshaw C, Gay D, Robertson F, Blain AP, Hudson G, Pyle A, Houghton D, Hunt M, Sampson JN, Stamp C, Mallett G, Amarnath S, Leslie J, Oakley F, Wilson L, Baker A, Russell OM, Johnson R, Richardson CA, Gupta B, McCallum I, McDonald SAC, Kelly S, Mathers JC, Heer R, Taylor RW, Perkins ND, Turnbull DM, Sansom OJ, Greaves LC. Age-associated mitochondrial DNA mutations cause metabolic remodeling that contributes to accelerated intestinal tumorigenesis. Nature Cancer. 2020; 1:976–989
Wilson DH, Jarman EJ, Mellin RP, Wilson ML, Waddell SH, Tsokkou P, Younger NT, Raven A, Bhalla SR, Noll ATR, Olde Damink SW, Schaap FG, Chen P, Bates DO, Banales JM, Dean CH, Henderson DJ, Sansom OJ, Kendall TJ, Boulter L. Non-canonical Wnt signalling regulates scarring in biliary disease via the planar cell polarity receptors. Nature communications. 2020; 11: 445.
2019
Allen-Petersen BL, Risom T, Feng Z, Wang Z, Jenny ZP, Thoma MC, Pelz KR, Morton JP, Sansom OJ, Lopez CD, Sheppard B, Christensen DJ, Ohlmeyer M, Narla G, Sears RC. Activation of PP2A and inhibition of mTOR synergistically reduce MYC signaling and decrease tumor growth in pancreatic ductal adenocarcinoma. Cancer Res 2019; 79: 209-219
Cosimo E, Tarafdar A, Moles MW, Holroyd AK, Malik N, Catherwood MA, Hay J, Dunn KM, Macdonald AM, Guichard SM, O'Rourke DM, Leach MT, Sansom OJ, Cosulich SC, McCaig AM, et al. AKT/mTORC2 inhibition activates FOXO1 function in CLL cells reducing B cell receptor-mediated survival. Clin Cancer Res 2019; 25: 1574-1587
Gay DM, Ridgway RA, Mueller M, Hodder MC, Hedley A, Clark W, Leach JD, Jackstadt R, Nixon C, Huels DJ, Campbell AD, Bird TG, Sansom OJ. Loss of BCL9/9l suppresses Wnt driven tumourigenesis in models that recapitulate human cancer. Nature communications 2019; 10: 723.
Jackstadt R, van Hooff SR, Leach JD, Cortes-Lavaud X, Lohuis JO, Ridgway RA, Wouters VM, Roper J, Kendall TJ, Roxburgh CS, Horgan PG, Nixon C, Nourse C, Gunzer M, Clark W, Hedley A, Yilmaz OH, Rashid M, Bailey P, Biankin AV, Campbell AD, Adams DJ, Barry ST, Steele CW, Medema JP, Sansom OJ. Epithelial NOTCH Signaling Rewires the Tumor Microenvironment of Colorectal Cancer to Drive Poor-Prognosis Subtypes and Metastasis. Cancer cell. 2019; 36: 19-336.e317.
Johansson J, Naszai M, Hodder MC, Pickering KA, Miller BW, Ridgway RA, Yu Y, Peschard P, Brachmann S, Campbell AD, Cordero JB, Sansom OJ. RAL GTPases Drive Intestinal Stem Cell Function and Regeneration through Internalization of WNT Signalosomes. Cell Stem Cell. 2019; 24: 592-607.e7.
Kugeratski FG, Atkinson SJ, Neilson LJ, Lilla S, Knight JRP, Serneels J, Juin A, Ismail S, Bryant DM, Markert EK, Machesky LM, Mazzone M, Sansom OJ, Zanivan S. Hypoxic cancer-associated fibroblasts increase NCBP2-AS2/HIAR to promote endothelial sprouting through enhanced VEGF signaling. Science signaling 2019; 12. pii: eaan8247.
Leach J, Morton JP, Sansom OJ. Neutrophils: Homing in on the myeloid mechanisms of metastasis. Molecular immunology. 2019;110:69-76.
Liko D, Mitchell L, Campbell KJ, Ridgway RA, Jones C, Dudek K, King A, Bryson S, Stevenson D, Blyth K, Strathdee D, Morton JP, Bird TG, Knight JRP, Willis AE, Sansom OJ. Brf1 loss and not overexpression disrupts tissues homeostasis in the intestine, liver and pancreas. Cell Death Differ. 2019; 26: 2535–2550
Malik N, Dunn KM, Cassels J, Hay J, Estell C, Sansom OJ, Michie AM. mTORC1 activity is essential for erythropoiesis and B cell lineage commitment. Scientific reports. 2019; 9: 16917.
Menon M, Elliott R, Bowers L, Balan N, Rafiq R, Costa-Cabral S, Munkonge F, Trinidade I, Porter R, Campbell AD, Johnson ER, Esdar C, Buchstaller HP, Leuthner B, Rohdich F, et al. A novel tankyrase inhibitor, MSC2504877, enhances the effects of clinical CDK4/6 inhibitors. Scientific reports 2019; 9: 201.
Reader CS, Vallath S, Steele CW, Haider S, Brentnall A, Desai A, Moore KM, Jamieson NB, Chang D, Bailey P, Scarpa A, Lawlor R, Chelala C, Keyse SM, Biankin A, Morton JP, Evans TRJ, Barry ST, Sansom OJ, Kocher HM, Marshall JF. The integrin alphavbeta6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. The Journal of pathology. 2019; 249: 332–342
Rohwer N, Jumpertz S, Erdem M, Egners A, Warzecha KT, Fragoulis A, Kuhl AA, Kramann R, Neuss S, Rudolph I, Endermann T, Zasada C, Apostolova I, Gerling M, Kempa S, Hughes R, Lewis CE, Brenner W, Malinowski MB, Stockmann M, Schomburg L, Faller W, Sansom OJ, Tacke F, Morkel M, Cramer T. Non-canonical HIF-1 stabilization contributes to intestinal tumorigenesis. Oncogene. 2019; 38: 5670-5685.
Spender LC, Ferguson JG, Hughes GD, Davies BR, Goldberg FW, Herrera B, Taylor RG, Strathearn LS, Sansom OJ, Barry ST, Inman GJ. Preclinical evaluation of AZ12601011 and AZ12799734, inhibitors of transforming growth factor beta superfamily type 1 receptors. Mol Pharmacol 2019; 95: 222-234
Schmidt S, Gay D, Uthe FW, Denk S, Paauwe M, Matthes N, Diefenbacher ME, Bryson S, Warrander FC, Erhard F, Ade CP, Baluapuri A, Walz S, Jackstadt R, Ford C, Vlachogiannis G, Valeri N, Otto C, Schulein-Volk C, Maurus K, Schmitz W, Knight JRP, Wolf E, Strathdee D, Schulze A, Germer CT, Rosenwald A, Sansom OJ, Eilers M, Wiegering A. A MYC-GCN2-eIF2alpha negative feedback loop limits protein synthesis to prevent MYC-dependent apoptosis in colorectal cancer. Nature cell biology. 2019; 21: 1413–1424
Vennin C, Melenec P, Rouet R, Nobis M, Cazet AS, Murphy KJ, Herrmann D, Reed DA, Lucas MC, Warren SC, Elgundi Z, Pinese M, Kalna G, Roden D, Samuel M, Zaratzian A, Grey ST, Da Silva A, Leung W, Mathivanan S, Wang Y, Braithwaite AW, Christ D, Benda A, Parkin A, Phillips PA, Whitelock JM, Gill AJ, Sansom OJ, Croucher DR, Parker BL, Pajic M, Morton JP, Cox TR, Timpson P. CAF hierarchy driven by pancreatic cancer cell p53-status creates a pro-metastatic and chemoresistant environment via perlecan. Nature communications. 2019; 10: 3637.
2018
Besray Unal E, Kiel C, Benisty H, Campbell A, Pickering K, Bluthgen N, Sansom OJ, Serrano L. Systems level expression correlation of Ras GTPase regulators. Cell Commun Signal. 2018; 16: 46.
Bird TG, Muller M, Boulter L, Vincent DF, Ridgway RA, Lopez-Guadamillas E, Lu WY, Jamieson T, Govaere O, Campbell AD, Ferreira-Gonzalez S, Cole AM, Hay T, Simpson KJ, Clark W, et al. TGFbeta inhibition restores a regenerative response in acute liver injury by suppressing paracrine senescence. Sci Transl Med 2018; 10: eaan1230
Burke ZD, Reed KR, Yeh SW, Meniel V, Sansom OJ, Clarke AR, Tosh D. Spatiotemporal regulation of liver development by the Wnt/beta-catenin pathway. Sci Rep 2018; 8: 2735
Candido JB, Morton JP, Bailey P, Campbell AD, Karim SA, Jamieson T, Lapienyte L, Gopinathan A, Clark W, McGhee EJ, Wang J, Escorcio-Correia M, Zollinger R, Roshani R, Drew L, Rishi L, Arkell R, Evans TRJ, Nixon C, Jodrell DI et al. CSF1R(+) Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype. Cell Rep 2018; 23: 1448-60
Chou A, Froio D, Nagrial AM, Parkin A, Murphy KJ, Chin VT, Wohl D, Steinmann A, Stark R, Drury A, Walters SN, Vennin C, Burgess A, Pinese M, Chantrill LA, et al. Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer. Gut 2018; 67: 2142-55
Conway JRW, Warren SC, Herrmann D, Murphy KJ, Cazet AS, Vennin C, Shearer RF, Killen MJ, Magenau A, Melenec P, Pinese M, Nobis M, Zaratzian A, Boulghourjian A, Da Silva AM, Del Monte-Nieto G, Adam ASA, Harvey RP, Haigh JJ, Wang Y et al. Intravital Imaging to Monitor Therapeutic Response in Moving Hypoxic Regions Resistant to PI3K Pathway Targeting in Pancreatic Cancer. Cell Rep 2018; 23: 3312-26
Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G, Sacchetto L, Chiorino G, De Laurenzi V, Piantelli M, Sansom OJ, Maffucci T, Falasca M. GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene 2018; 37: 6368–6382
Flanagan DJ, Hodder MC, Sansom OJ. Microenvironmental cues in cancer stemness. Nat Cell Biol 2018; 20: 1102-4.
Foth M, Ismail NFB, Kung JSC, Tomlinson D, Knowles MA, Eriksson P, Sjodahl G, Salmond JM, Sansom OJ, Iwata T. FGFR3 mutation increases bladder tumorigenesis by suppressing acute inflammation. J Pathol 2018; 246: 331-343
Godfrey JD, Morton JP, Wilczynska A, Sansom OJ, Bushell MD. MiR-142-3p is downregulated in aggressive p53 mutant mouse models of pancreatic ductal adenocarcinoma by hypermethylation of its locus. Cell Death Dis 2018; 9: 644
Greenhough A, Bagley C, Heesom KJ, Gurevich DB, Gay D, Bond M, Collard TJ, Paraskeva C, Martin P, Sansom OJ, Malik K, Williams AC. Cancer cell adaptation to hypoxia involves a HIF-GPRC5A-YAP axis. EMBO Mol Med. 2018 10: e8699
Huels DJ, Bruens L, Hodder MC, Cammareri P, Campbell AD, Ridgway RA, Gay DM, Solar-Abboud M, Faller WJ, Nixon C, Zeiger LB, McLaughlin ME, Morrissey E, Winton DJ, Snippert HJ, van Rheenen J, Sansom OJ. Wnt ligands influence tumour initiation by controlling the number of intestinal stem cells. Nat Commun 2018; 9: 1132
Malik N, Sansom OJ, Michie AM. The role of mTOR-mediated signals during haemopoiesis and lineage commitment. Biochem Soc Trans 2018; 46: 1313–1324.
Martin KJ, McGhee EJ, Schwarz JP, Drysdale M, Brachmann SM, Stucke V, Sansom OJ, Anderson KI. Accepting from the best donor; analysis of long-lifetime donor fluorescent protein pairings to optimise dynamic FLIM-based FRET experiments. PLoS One 2018; 13: e0183585
May S, Owen H, Phesse TJ, Greenow KR, Jones GR, Blackwood A, Cook PC, Towers C, Gallimore AM, Williams GT, Sturzl M, Britzen-Laurent N, Sansom OJ, MacDonald AS, Bird AP, Clarke AR, Parry L. Mbd2 enables tumourigenesis within the intestine while preventing tumour-promoting inflammation. J Pathol 2018; 245: 270-82
Monteverde T, Tait-Mulder J, Hedley A, Knight JR, Sansom OJ, Murphy DJ. Calcium signalling links MYC to NUAK1. Oncogene 2018; 37: 982-92
Morris HT, Fort L, Spence HJ, Patel R, Vincent DF, Park JH, Snapper SB, Carey FA, Sansom OJ, Machesky LM. Loss of N-WASP drives early progression in an Apc model of intestinal tumourigenesis. J Pathol 2018; 245: 337-48
Patel R, Fleming J, Mui E, Loveridge C, Repiscak P, Blomme A, Harle V, Salji M, Ahmad I, Teo K, Hamdy FC, Hedley A, van den Broek N, Mackay G, Edwards J, Sansom OJ, Leung HY. Sprouty2 loss-induced IL6 drives castration-resistant prostate cancer through scavenger receptor B1. EMBO Mol Med 2018; 10: e8347
Pearson HB, Li J, Meniel VS, Fennell CM, Waring P, Montgomery KG, Rebello RJ, Macpherson AA, Koushyar S, Furic L, Cullinane C, Clarkson RW, Smalley MJ, Simpson KJ, Phesse TJ, Shepherd PR, Humbert PO, Sansom OJ, Phillips WA. Identification of Pik3ca Mutation as a Genetic Driver of Prostate Cancer That Cooperates with Pten Loss to Accelerate Progression and Castration-Resistant Growth. Cancer Discov 2018; 8: 764-79
Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, Hedley A, Kalna G, Lilla S, Neilson L, Brucoli M, Gyuraszova K, Tait-Mulder J, Mezna M, Svambaryte S, Bryson A, Sumpton D, McVie A, Nixon C, Drysdale M et al. Colorectal Tumors Require NUAK1 for Protection from Oxidative Stress. Cancer Discov 2018; 8: 632-47
Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, Lampis A, Eason K, Huntingford I, Burke R, Rata M, Koh DM, Tunariu N, Collins D, Hulkki-Wilson S, Ragulan C, Spiteri I, Moorcraft SY, Chau I, Rao S et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science 2018; 359: 920-6
Woroniuk A, Porter A, White G, Newman DT, Diamantopoulou Z, Waring T, Rooney C, Strathdee D, Marston DJ, Hahn KM, Sansom OJ, Zech T, Malliri A. STEF/TIAM2-mediated Rac1 activity at the nuclear envelope regulates the perinuclear actin cap. Nat Commun 2018; 9: 2124
Ahmad I, Sansom OJ. Role of Wnt signalling in advanced prostate cancer. J Pathol 2018; 245: 3-5
Hodder MC, Flanagan DJ, Sansom OJ. Intestinal Stem Cell Dynamics: A Story of Mice and Humans. Cell Stem Cell 2018; 22: 785-7
Research Team Leader
Andrew Campbell
I’m a research team leader in Owen Sansom’s group. I’m really interested in understanding how common cancer-causing mutations and activation of cancer-associated signalling pathways contribute to the development and spread of colorectal cancer (CRC). Building our knowledge of how these pathways are regulated helps us to understand how tumours respond to current treatments, and helps us to design new, even more effective ways of treating patients. Before joining the group, I completed both a BSc and PhD at the University of Dundee, and postdoctoral training here at the CRUK Scotland Institute with Brad Ozanne and Jim Norman. Outside of research, I love spending time with my family, and life on a hillside in rural Scotland.
Group Research Manager
Rachel Ridgway
I am the lab research manager in Owen’s group with a focus on developing new complex models of colorectal cancer (CRC). The aim of this research is to improve treatment options for patients. Other research areas include studying the cell of origin for cancer, therapeutic vulnerabilities and working with complex models of CRC metastasis.
Prior to joining Owen’s group I completed my BSc and PhD at Cardiff University. Outside of work I enjoy swimming, Parkrun, walking, as well visiting many of the great restaurants and pubs in Glasgow.
Clinical Lecturer
Mark White
I am a Clinical Lecturer in Medical Oncology at the CRUK Scotland Institute and the University of Glasgow, and I am based clinically at the Beatson West of Scotland Cancer Centre. My clinical and research interests are in colorectal cancer, with a particular focus on BRAF-mutant disease, therapeutic resistance and tumour epithelial plasticity. My work aims to combine mechanistic and translational research to better understand how advanced colorectal cancers evolve, adapt and resist therapy, with the overarching goal of developing novel therapeutic strategies for people with advanced colorectal cancer. I am part of the CRUK CRC STARS research consortium and study physician for the FOxTROT 4 study, contributing to collaborative translational research programmes that link laboratory discovery with clinical impact.
Scientific Writer
Nathalie Sphyris
As an experienced scientific writer, I help lab members communicate complex scientific concepts and build compelling narratives, whilst also promoting adherence to scientific integrity. My longstanding interest in epithelial cell plasticity and avid literature searching help me keep pace with a rapidly evolving research landscape, critically appraise manuscripts, and contribute to the interpretation of data. I was previously an Instructor/Junior Faculty at MD Anderson Cancer Center (Houston, TX, USA), where I studied the role of the epithelial–mesenchymal transition in breast cancer and cultivated skills in grantsmanship, project management, and strategic planning. As a postdoc (University of Edinburgh, Edinburgh, UK), I investigated the role of p53-pathway components in embryonic stem cells, pancreatic acinar-ductal transdifferentiation, and zebrafish embryonic gut development, consolidating my interest in hybrid cellular identities and epithelial plasticity. Outside of work, I enjoy getting out and about in nature, photography, and visiting art galleries and craft fairs.
Bioinfomatician
Kathryn Gilroy
I am a senior bioinformatician in the lab, supporting everyone in the group with their data analysis needs. This involves analysis of bulk and single cell RNAseq data, epigenetic data, genomic data, and spatial transcriptomic data. Before moving into bioinformatics, I completed a PhD and two post-docs as a bench scientist, focussing on molecular and cellular biology in cancer. Outside of work I run a scout section and try to get out in nature as often as I can.
Bioinfomatician
Yourae Hong*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Bioinfomatician
Rosalin Simpson
I'm Rosalin a Bioinformatician within the Sansom lab, assisting the group with their bioinformatics analysis by analysing transcriptomic data such as bulk or single-cell RNA-sequencing. Before coming to the Institute, I carried out an MSci in bioinformatics at the University of Dundee and a PhD in biological sciences at the University of Aberdeen examining transcriptome plasticity responses to environmental stress. Now at CRUK SI I'm excited to be applying my bioinformatics experience to cancer research. Outside of work I enjoy baking, video games and live music.
Translational Scientist
Ainsley Antao*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Postdoctoral Researcher
Patricia Centeno
I am a postdoctoral researcher working on melanoma and non-melanoma skin cancer. I am interested in how skin cells communicate and how do they response to oncogenic mutations. I am part of the Grand Challenge Specificancer team looking at the tissue specificity of cancer genes. I am Postdoc representative of the CRUK-SI institute and passionate about promoting Women in STEM. Outside the lab, I enjoy travelling to sunny destinations, yoga and recently Crossfit.
Postdoctoral Researcher
Nuray Gunduz
I am a postdoctoral researcher focusing on the role of LGR family proteins in colorectal cancer. I am also part of the Grand Challenge Specificancer team, where we explore the inter-tissue specificity of cancer genes.
In addition to my research, I enjoy organizing events that support networking and career development for young scientists and currently serve as the Scientific Coordinator for the 2025 FEBS-IUBMB-ENABLE Conference.
Prior to joining the Cancer Research UK Scotland Institute, I completed my PhD at Bilkent University in Turkey, where my research focused on nano-biomaterials and their applications in regenerative medicine, during last year of my PhD, I was visiting researcher at the Yilmaz Lab at the Koch Institute for Integrative Cancer Research at MIT. I hold a BSc (Hons) in Molecular Biology and Genetics from Istanbul University.
Outside of the lab, I enjoy cooking, taking long walks in nature and watercolor painting.
Postdoctoral Researcher
Kimberly Hartl*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Postdoctoral Researcher
Andrew Hartley
I am a post-doctoral research scientist focusing on the development of cancer in the intestine. I am investigating colorectal cancer dependency on β-Catenin using in vivo murine models with an aim of developing degron technology to model therapeutics. My research interests include understanding the epigenetic processes as an intestinal stem cell rewires to become a cancer stem cell. In my spare time I like to play chess, DnD, and go on hikes with my dog.
Postdoctoral Researcher
Georgios Kanellos
I completed my degree in Biology at the Aristotle University of Thessaloniki before moving to the UK for an MRes at the University of York. During this time, I joined the London Research Institute, where I worked on DNA damage response and developed a strong interest in cancer research.
I went on to pursue a PhD in cancer biology at the University of Edinburgh, investigating the role of cytoskeleton-regulating proteins, which are critical for cell invasion and metastasis. I then joined Owen Sansom’s group at the CRUK Scotland Institute as a postdoctoral researcher, to expand on the genetic perturbations that drive cancers with defined molecular profiles and contribute to projects focused on identifying new therapeutic targets within the protein synthesis space.
Postdoctoral Researcher
Nadia Nasreddin
I am a postdoctoral researcher scientist interested in the intestinal stem cell dynamics, the role of the WNT signalling pathway in carcinogenesis and the interplay between inflammation and carcinogenesis. I joined the Sansom group in 2023 to work on the role of the WNT signalling pathway in colorectal cancer. My current projects include investigating novel preventative strategies for colorectal cancer and the role of inflammation in carcinogenesis.
I am a molecular biologist by training having undertaken my undergraduate studies in Biomedical Sciences at the University of Westminster, followed by a MSc in Human Molecular Genetics at Imperial College London. Prior to joining the Sansom group, I undertook a DPhil at the University of Oxford working on the molecular and histological characterisation of colitis-associated colorectal cancer.
In addition to my research work, I am very passionate about working towards a more diverse and inclusive academia. As such, I am involved in EDI initiatives and public engagement projects that aim to foster diversity and inclusion in academia, including volunteering as a mentor and host for the charity in2STEMUK. I am also the ECR representative of the WNTUK committee, where I work to better support ECRs within the network and build a strong WNT community.
Postdoctoral Researcher
Nalle Pentinmikko*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Postdoctoral Researcher
Susanti Susanti
I am a Postdoctoral Research Scientist in the laboratory of Professor Owen Sansom at the CRUK Scotland Institute, Glasgow. My research focuses on intestinal stem cell phenotypes and the spectrum of epithelial cell states within colorectal cancer, with a particular interest in how Wnt and regenerative signalling pathways drive tumour initiation and progression. I am especially interested in early-onset colorectal cancer, disease diagnosed under the age of 50, and the modifiable biological factors that may accelerate its development in younger adults.
Originally from Indonesia, I completed my PhD at the University of Nottingham investigating the molecular and tumour microenvironment features of colorectal cancer for biomarker discovery, followed by a first postdoctoral position at the same institution. As a colorectal cancer survivor, I bring a distinctly patient-informed perspective to my research, ensuring that the questions I ask remain grounded in what matters most to patients and those living beyond cancer.
Postdoctoral Researcher
Ayse Yazgilli
I am a postdoctoral research scientist focused on uncovering the molecular mechanisms that drive cancer initiation and resistance to therapy. I hold a BSc in Molecular Biology and Genetics from Istanbul Technical University, where I completed my thesis at Umeå University, Sweden, through an Erasmus scholarship. I went on to earn an MSc from Koç University, where I studied the interaction between KRAS and CRAF using molecular dynamic simulations, with a focus on mutations in lung cancer.
During my PhD at Ludwig Maximilian University (LMU), I investigated the functional role of a proteasome activator in lung cancer. In 2023, I joined the Sansom Group as a Senior Scientific Officer, where I worked on novel treatment strategies and drug repurposing for colorectal cancer. Since 2024, I have been working as a postdoctoral researcher, focusing on identifying molecular vulnerabilities and resistance mechanisms with the goal of improving therapeutic outcomes for patients with colorectal cancer.
Outside of work, I enjoy reading, watching movies, nature walks, hiking and playing board and video games.
Principal Scientific Officer
Catriona Ford
I am a Principal Scientific Officer in the Colorectal Cancer and WNT Signalling Group at the CRUK Scotland Institute. I am part of a vibrant and enthusiastic team that utilise in vivo mouse models alongside in vitro skills such as organoid cell culture to better understand disease progression and response to therapy. In addition to the various research projects that I am involved in, I support the smooth running of the lab, training of staff/students and manage our cell banks. Aside from work, I like to spend time with family, friends & church; I enjoy keeping active & getting outdoors.
Principal Scientific Officer
Karen Strathdee*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Senior Scientific Officer
Sara Al-Badran
Sara is a Senior Scientific Officer in the Sansom group. She graduated from the University of Nottingham in 2018 with a BSc in Biomedical Sciences with Honours. She then joined the University of Glasgow to undertake her MSc in Cancer Sciences, graduating with distinction in 2019, then completing her PhD in the Edward Lab in 2025.
Sara joined INCISE at the start of her PhD in 2021, to investigate the polyp microbiome and possible related pathways, and their effect on the development of future polyps. Sara is using a variety of techniques for this, including immunohistochemistry, TempO-Seq, RNAscope, and CosMX. Sara’s previous research interests include housekeeping gene identification for microRNA research, and using immune checkpoints as prognostic biomarkers for colorectal cancer.
In her free time, she enjoys going to the cinema and Star Trek marathons.
Senior Scientific Officer
Connor Brown*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Senior Scientific Officer
Jasmine Ho
I am Jasmine, a PhD student from Hong Kong. Currently at Professor Owen Sansom’s group, I am studying the role of NFκB signalling in metastasis of colorectal cancer using genetically engineered mouse models. Prior my PhD, I completed my undergraduate degree in Biochemistry at Imperial College London and undertook an industrial placement at GSK Cell and Gene Therapy Discovery Research unit. Outside the lab, I enjoy doing aerial silks, cooking and travelling.
Senior Scientific Officer
Sonia Rolo*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Senior Scientific Officer
Maria Silva*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Clinical Research Fellow
Kyrillus Shohdy*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
Clinical Research Fellow
Roberta Garau*
Information about this team member’s research interests, experience, and background will be added soon. Please check back for updates.
PhD Student
Krittaya Aksonnam
I am Krittaya, a PhD student who joined the Sansom Lab in 2024. My research focuses on understanding how KRAS inhibition remodels the tumour microenvironment in colorectal cancer, with a particular interest in the interactions between cancer cells and the immune system. Before joining the CRUK Scotland Institute, I completed a BSc in Computational Science and an MSc in Immunology in Thailand. Outside the lab, I enjoy travelling, hiking, and cooking.
PhD Student
Nelson Awuah Ankamah
I am a PhD student co-supervised by Prof. Owen Sansom (CRUK Scotland Institute) and Prof. Vincenzo D’Angiolella (Institute of Genetics and Cancer), focusing on the molecular mechanisms driving colorectal cancer (CRC). My current research investigates the roles of the E3 ubiquitin ligase RNF43 and the ubiquitin-like protein ISG15 in CRC progression and treatment.
Originally from Ghana, I earned my Doctor of Pharmacy (PharmD) degree and practiced in Internal Medicine before transitioning to scientific research. I hold a dual master’s degree in Sustainable Drug Discovery (Ghent University & Medical University of Gdańsk) and Medical Pharmaceutical Sciences (University of Groningen). I completed my master’s thesis in Prof. Stefan Knapp’s lab at the Structural Genomics Consortium (SGC) in Frankfurt and later worked on CAR-T cell therapy with Legend Biotech and Johnson & Johnson Innovative Medicine.
When the lab coat comes off, I wonder about the mysteries of the universe. As an avid astrophysics enthusiast, I am deeply fascinated by the tension between relativity and quantum mechanics. Beyond the cosmos, I enjoy playing and watching football, cycling, and channelling my inner chef in the kitchen.
PhD Student
Megan Mills
My name is Megan, I am a PhD student focusing on metastatic development in advanced preclinical models of BRAF mutant colorectal cancer and how the tumour microenvironment may influence this. I completed my undergraduate degree in Veterinary Biosciences and masters degree in Cancer Research and Precision Oncology at the University of Glasgow and went on to work as a Scientific Officer in the Sansom lab for 2-years prior to my PhD. Outside of the lab, I enjoy travelling, live music and cooking.
PhD Student
Sarah Williams
My name is Sarah, and I am a PhD student form London, UK. I completed my Bachelor’s and Masters in Biochemistry at the University of York and went on to work on CAR-T cells in the Biotech Company, Autolus. I moved to the Sansom lab to study the role the immune microenvironment has on the metastatic tropism of colorectal cancer with a particular focus on macrophages. I am also passionate about increasing diversity in the cancer research field. Outside of work I enjoy exploring travelling, running and painting.